EUVIMEDEUVIMED entdecken
Crossref

Tumor-Agnostic Circulating Tumor DNA Analysis as a Comprehensive Predictive Biomarker of Recurrence after Ablative Radiotherapy for Early-Stage Non-Small Cell Lung Cancer

Masaki Nakamura, Shun-Ichiro Kageyama, Hidenari Hirata, Masaki Ohira, Shunsuke A Sakai, Yumi Hakozaki, Hidehiro Hojo, Takeshi Fujisawa, Riu Yamashita, Hiroshi Haeno, Akinori Kanai, Yutaka Suzuki und 3 weitere

Clinical Lung Cancer · 2025

DOI: 10.1016/j.cllc.2025.09.013 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Lung Cancer, 2025. Verfasst von Masaki Nakamura und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, National Cancer Center Hospital East, Chiba, Japan; Course of Advanced Clinical Research of Cancer, Juntendo Univer…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Circulating Tumor DNA, Biomarkers, Tumor. Die Arbeit nennt 33 Literaturangaben. Gefördert von: Yasuda Memorial Medical Foundation, Illumina, Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: This study aimed to evaluate whether pretreatment circulating tumor DNA (ctDNA) is a predictive biomarker for recurrence in patients with early-stage non-small cell lung cancer (ES-NSCLC), including those with pathologically unproven (PU) who received ablative radiotherapy. MATERIALS AND METHODS: Patients clinically diagnosed with cT1-2N0M0 NSCLC treated with radiotherapy alone at a single institute were included. Pretreatment plasma and matched white blood cell samples were subjected to targeted sequencing to detect ctDNA. The association between ctDNA detection and prognosis was evaluated. Integrated analysis including non-squamous cell carcinoma (SQ) cohort and enhancement of recurrence prediction with radiographic features were also evaluated. RESULTS: Of the 19 patients (10 SQ, and 9 PU) who met the sequence quality criteria, ctDNA was detected in 6. At the median follow-up of 60 months, detectable ctDNA was significantly associated with inferior progression-free survival (PFS) in both the SQ and PU cohorts (P = .01 and .02). In an analysis of 62 patients combined with the non-SQ cohort, ctDNA detection was the only significant factor for PFS. The combination of ctDNA and a high positron emission tomography maximum standardized uptake value provided a better recurrence risk model than ctDNA alone (the C-index improved from 0.63 to 0.72). CONCLUSION: These results suggest that pretreatment ctDNA detection can predict recurrence in patients with cT1-2N0M0 NSCLC, including those with PU tumors treated with ablative radiotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsCirculating Tumor DNABiomarkers, TumorNeoplasm Recurrence, LocalHumansMaleFemaleAgedMiddle AgedPrognosisFollow-Up StudiesNeoplasm StagingAged, 80 and overSurvival RateAdultRetrospective Studies

Stichwörter der Autor:innen

NSCLCctDNAliquid biopsyradiotherapytumor-agnostic

Substanzen

Circulating Tumor DNABiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Radiation Oncology, National Cancer Center Hospital East, Chiba, Japan; Course of Advanced Clinical Research of Cancer, Juntendo University Graduate School of Medicine, Tokyo, Japan. Electronic address: ma…
  • Division of Particle Therapy, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Chiba, Japan.
  • Department of Radiation Oncology, National Cancer Center Hospital East, Chiba, Japan.
  • Division of Translational Informatics, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Chiba, Japan.
  • Department of Research Institute for Biomedical Sciences, Tokyo University of Science, Chiba, Japan.
  • Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Chiba, Japan.

Förderung

  • Yasuda Memorial Medical Foundation
  • Illumina
  • Japan Society for the Promotion of Science
  • Japan Agency for Medical Research and Development

Zitieren

APA

Nakamura, M., Kageyama, S. I., Hirata, H., Ohira, M., Sakai, S. A., Hakozaki, Y., Hojo, H., Fujisawa, T., Yamashita, R., Haeno, H., Kanai, A., Suzuki, Y., Yamaguchi, M., Tsuchihara, K., & Zenda, S. (2025). Tumor-Agnostic Circulating Tumor DNA Analysis as a Comprehensive Predictive Biomarker of Recurrence after Ablative Radiotherapy for Early-Stage Non-Small Cell Lung Cancer. Clinical Lung Cancer. https://doi.org/10.1016/j.cllc.2025.09.013

Vancouver

Nakamura M, Kageyama SI, Hirata H, Ohira M, Sakai SA, Hakozaki Y, et al. Tumor-Agnostic Circulating Tumor DNA Analysis as a Comprehensive Predictive Biomarker of Recurrence after Ablative Radiotherapy for Early-Stage Non-Small Cell Lung Cancer. Clinical Lung Cancer. 2025. doi:10.1016/j.cllc.2025.09.013

BibTeX
@article{Nakamura2025,
  author = {Nakamura, Masaki and Kageyama, Shun-Ichiro and Hirata, Hidenari and Ohira, Masaki and Sakai, Shunsuke A and Hakozaki, Yumi and Hojo, Hidehiro and Fujisawa, Takeshi and Yamashita, Riu and Haeno, Hiroshi and Kanai, Akinori and Suzuki, Yutaka and Yamaguchi, Masayuki and Tsuchihara, Katsuya and Zenda, Sadamoto},
  title = {Tumor-Agnostic Circulating Tumor DNA Analysis as a Comprehensive Predictive Biomarker of Recurrence after Ablative Radiotherapy for Early-Stage Non-Small Cell Lung Cancer},
  journal = {Clinical Lung Cancer},
  year = {2025},
  doi = {10.1016/j.cllc.2025.09.013}
}
Kostenlos starten →